21 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp05061 | P369-CTL-A2xFVB | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 8% Inhibition at 10-10 M |
| dbacp05062 | P369-CTL-A2xFVB | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 25% Inhibition at 10-9 M |
| dbacp05063 | P369-CTL-A2xFVB | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 80% Inhibition at 10-8 M |
| dbacp05064 | P369-CTL-A2xFVB | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 85% Inhibition at 10-7 M |
| dbacp05065 | P369-CTL-A2xFVB | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 92% Inhibition at 10-6 M |
| dbacp05066 | P369-CTL-A2xneu | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 0.1% Inhibition at 10-10 M |
| dbacp05067 | P369-CTL-A2xneu | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 1% Inhibition at 10-9 M |
| dbacp05068 | P369-CTL-A2xneu | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 5% Inhibition at 10-8 M |
| dbacp05069 | P369-CTL-A2xneu | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 10% Inhibition at 10-7 M |
| dbacp05070 | P369-CTL-A2xneu | KIFGSLAFL | Synthetic Peptide | Antiangiogenis; Immune regulation | Peptide dose curve assay | N202.A2 | Tumor | 20% Inhibition at 10-6 M |
| dbacp06188 | T Peptide | TKPRKTKPRKTKPRKTKPR | Tuftsin derivative | Immune regulation | MTT/MTS assay | HepG-2 | Liver cancer | 69.6% maximum inhibitory rate at 8 mg/kg |
| dbacp06189 | T Peptide | TKPRKTKPRKTKPRKTKPR | Tuftsin derivative | Immune regulation | MTT/MTS assay | HT-29 | Colon cancer | 70% maximum inhibitory rate at 8 mg/kg |
| dbacp06190 | T Peptide | TKPRKTKPRKTKPRKTKPR | Tuftsin derivative | Immune regulation | MTT/MTS assay | BGC-823 | Gastric cancer | 67.2% maximum inhibitory rate at 8 mg/kg |
| dbacp06404 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 49.4% Cytotoxic at 0.1 µg/ml |
| dbacp06405 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 51.2% Cytotoxic at 1 µg/ml |
| dbacp06406 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 53.0% Cytotoxic at 10 µg/ml |
| dbacp06407 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | B16-F10 | Skin cancer | 61.2% Cytotoxic at 100 µg/ml |
| dbacp06408 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | BEL-7402 | Liver cancer | 39.0% Cytotoxic at 0.1 µg/ml |
| dbacp06409 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | BEL-7402 | Liver cancer | 20.8% Cytotoxic at 1 µg/ml |
| dbacp06410 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | BEL-7402 | Liver cancer | 33.8% Cytotoxic at 10 µg/ml |
| dbacp06411 | Tyroserleutide | YSL | Synthetic Peptide | Necrosis; Immune regulation | MTT/MTS assay | BEL-7402 | Liver cancer | 35.6% Cytotoxic at 100 µg/ml |